

SAAKSHI MEDTECH AND PANELS LIMITED

Regd. Office Address: Plot No. El-23, J Block, MIDC Industrial Area, Bhosari, Pune - 411026,
Maharashtra, India, 411026

Email Id: aniket.l@smtpl.co

Website: www.smtpl.co

Contact Details: 020 39854400 / 020 39854401

Date: September 12, 2026

To,
Listing Compliance Department,
National Stock Exchange of India Limited,
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (East)
Mumbai 400051

ISIN: **INE0PSK01027**

Symbol: **SAAKSHI**

Dear Sir/Madam,


Subject: Receipt of In - Principle approval for listing of 2010259 Equity shares of Rs. 10/- each allotted on preferential basis.

In compliance with Regulation 30 read with Schedule III, Para A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("**SEBI Listing Regulations**") read with SEBI master circular dated November 11, 2024 on SEBI Listing Regulations, this is to inform you that the Company has received In-Principle approval from NSE vide letter no. NSE/LIST/57127 dated September 11, 2026 for listing of 2010259 Equity shares of Rs. 10/- each allotted on preferential basis for consideration other than cash.

The information required under Regulation 30 read with SEBI master circular dated November 11, 2024 is enclosed as **Annexure-A**. The Copy of approval received from NSE is enclosed herewith.

Thanking You,

For Saakshi Medtech and Panels Limited



Mrs. Mayuri Aniket Latkar
Chief Financial Officer and Director
DIN: 03312077

CIN: U51909PN2009PLC133690

SAAKSHI MEDTECH AND PANELS LIMITED

Regd. Office Address: Plot No. El-23, J Block, MIDC Industrial Area, Bhosari, Pune - 411026,
Maharashtra, India, 411026

Email Id: aniket.l@smtpl.co

Website: www.smtpl.co

Contact Details: 020 39854400 / 020 39854401

Annexure-A

The details as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 read with SEBI master circular dated November 11, 2024 are mentioned below:

Sr. No.	Particulars	Details
1.	Name of the Regulatory or licensing authority	NSE
2.	Brief details of the approval/license obtained/ withdrawn / surrendered	In - Principle approval for listing of 2010259 Equity shares of Rs. 10/- each allotted on preferential basis.
3.	Impact/relevance of such approval/license to the listed entity	NSE has granted in-principle approval for listing of 2010259 Equity shares of Rs. 10/- each allotted on preferential basis for the share swap transaction with Laxmi Engineering Industries Bhopal Pvt Ltd (Target Company), for consideration other than cash (share swap). The said shares would be listed and admitted to dealings on the Exchange on receipt of the confirmation from the depositories i.e. NSDL/CDSL for credit of beneficiaries' accounts.
4.	Withdrawal/cancellation or suspension of license/approval by the regulatory or licensing authority, with reasons, for such action, estimated impact (monetary or otherwise) on the listed entity and penalty. If any	NA
5.	Period for which such approval/license is valid	NA
6.	The Actual impact (monetary or otherwise) along with corrective actions taken by the listed Company pursuant to the withdrawal, cancellation or suspension of the key license/approval	Not Applicable

CIN: U51909PN2009PLC133690



Ref: NSE/LIST/57127

September 11, 2026

The Company Secretary
Saakshi Medtech and Panels Limited

Dear Sir/Madam,

Sub: In - Principle approval for listing of 2010259 Equity shares of Rs. 10/- each allotted on preferential basis.

We are in receipt of your application for in-principle approval for listing of 2010259 Equity shares of Rs. 10/- each allotted on preferential basis bearing distinctive numbers from 17656001 to 19666259.

We have perused the listing application and the related documents/details submitted by you for listing of the above shares.

We are pleased to grant the in-principle approval for listing of the above shares on the Exchange. The said shares would be listed and admitted to dealings on the Exchange on receipt of the confirmation from the depositories i.e. NSDL/CDSL for credit of beneficiaries' accounts.

The Exchange reserves its right to withdraw its in-principle approval for listing at a later stage if the information submitted to the Exchange is found to be incomplete/incorrect/misleading/false or in contravention of any Rules, Bye-laws and Regulations of the Exchange, SEBI (LODR) Regulations, 2015, Guidelines/ Regulations issued by statutory authorities, etc.

Yours faithfully,
For National Stock Exchange of India Limited

Tejashri Rampariya
Manager

Cc:
National Securities Depository Limited
Central Depository Services Limited

P.S. Checklist of all the further issues is available on website of the exchange at the following URL:
<https://www.nseindia.com/companies-listing/raising-capital-further-issues-main-sme-checklist>

The National Stock Exchange of India (NSE) has announced the launch of NEAPS mobile application. The app can be downloaded from the App Store/ Play store with the name "NEAPS APP"

This Document is Digitally Signed



Signed by: Tejashri Rampariya
Date: Fri, Sep 11, 2026 17:15:49 IST
Location: NSE